Browse BLVRB

Summary
SymbolBLVRB
Namebiliverdin reductase B
Aliases SDR43U1; short chain dehydrogenase/reductase family 43U, member 1; (flavin reductase (NADPH)); FLR; Flavin r ......
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF13460 NAD(P)H-binding
Function

Broad specificity oxidoreductase that catalyzes the NADPH-dependent reduction of a variety of flavins, such as riboflavin, FAD or FMN, biliverdins, methemoglobin and PQQ (pyrroloquinoline quinone). Contributes to heme catabolism and metabolizes linear tetrapyrroles. Can also reduce the complexed Fe(3+) iron to Fe(2+) in the presence of FMN and NADPH. In the liver, converts biliverdin to bilirubin.

> Gene Ontology
 
Biological Process GO:0006778 porphyrin-containing compound metabolic process
GO:0006787 porphyrin-containing compound catabolic process
GO:0019439 aromatic compound catabolic process
GO:0033013 tetrapyrrole metabolic process
GO:0033015 tetrapyrrole catabolic process
GO:0042167 heme catabolic process
GO:0042168 heme metabolic process
GO:0042440 pigment metabolic process
GO:0044270 cellular nitrogen compound catabolic process
GO:0046149 pigment catabolic process
GO:0046700 heterocycle catabolic process
GO:0051186 cofactor metabolic process
GO:0051187 cofactor catabolic process
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0004074 biliverdin reductase activity
GO:0016627 oxidoreductase activity, acting on the CH-CH group of donors
GO:0016628 oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor
GO:0016645 oxidoreductase activity, acting on the CH-NH group of donors
GO:0016646 oxidoreductase activity, acting on the CH-NH group of donors, NAD or NADP as acceptor
GO:0042602 riboflavin reductase (NADPH) activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00740 Riboflavin metabolism
hsa00860 Porphyrin and chlorophyll metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-189483: Heme degradation
R-HSA-1430728: Metabolism
R-HSA-189445: Metabolism of porphyrins
Summary
SymbolBLVRB
Namebiliverdin reductase B
Aliases SDR43U1; short chain dehydrogenase/reductase family 43U, member 1; (flavin reductase (NADPH)); FLR; Flavin r ......
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BLVRB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolBLVRB
Namebiliverdin reductase B
Aliases SDR43U1; short chain dehydrogenase/reductase family 43U, member 1; (flavin reductase (NADPH)); FLR; Flavin r ......
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BLVRB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen Total # shRNA with >= 4-fold: 3 Resistant to T-cell proliferation
Summary
SymbolBLVRB
Namebiliverdin reductase B
Aliases SDR43U1; short chain dehydrogenase/reductase family 43U, member 1; (flavin reductase (NADPH)); FLR; Flavin r ......
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BLVRB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.010.978
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2540.933
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1710.937
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4840.362
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0490.976
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.1640.589
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1910.649
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1910.89
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3860.827
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1220.957
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3080.932
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0220.842
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BLVRB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBLVRB
Namebiliverdin reductase B
Aliases SDR43U1; short chain dehydrogenase/reductase family 43U, member 1; (flavin reductase (NADPH)); FLR; Flavin r ......
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BLVRB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBLVRB
Namebiliverdin reductase B
Aliases SDR43U1; short chain dehydrogenase/reductase family 43U, member 1; (flavin reductase (NADPH)); FLR; Flavin r ......
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BLVRB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BLVRB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBLVRB
Namebiliverdin reductase B
Aliases SDR43U1; short chain dehydrogenase/reductase family 43U, member 1; (flavin reductase (NADPH)); FLR; Flavin r ......
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BLVRB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBLVRB
Namebiliverdin reductase B
Aliases SDR43U1; short chain dehydrogenase/reductase family 43U, member 1; (flavin reductase (NADPH)); FLR; Flavin r ......
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BLVRB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBLVRB
Namebiliverdin reductase B
Aliases SDR43U1; short chain dehydrogenase/reductase family 43U, member 1; (flavin reductase (NADPH)); FLR; Flavin r ......
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BLVRB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBLVRB
Namebiliverdin reductase B
Aliases SDR43U1; short chain dehydrogenase/reductase family 43U, member 1; (flavin reductase (NADPH)); FLR; Flavin r ......
Chromosomal Location19q13.1-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BLVRB collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting BLVRB.
ID Name Drug Type Targets #Targets
DB00140RiboflavinSmall MoleculeBLVRB, RFK2
DB00157NADHSmall MoleculeAASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......144
DB02073Biliverdine IX AlphaSmall MoleculeBLVRB, HMOX1, MB3
DB03247Flavin mononucleotideSmall MoleculeBLVRB, DHODH, DPYD, HAO1, HAO2, NOS1, PNPO, POR, PPCDC, RFK, RPS6K ......12
DB034612'-Monophosphoadenosine 5'-DiphosphoriboseSmall MoleculeADH1B, AKR1A1, AKR1B1, AKR1B10, AKR1C1, AKR1C2, AKR1C3, BLVRB, CRY ......28
DB043457,8-dimethylalloxazineSmall MoleculeBLVRB1
DB04363Mesobiliverdin Iv AlphaSmall MoleculeBLVRB1